Today’s guest post is by Avinash Amarnath ([email protected]) of Vinod Dhall and TT&A.

*******************************************************************************************

CCI fines GSK and Sanofi for bid rigging

It has been quite a while since I posted an India update on Cartel Capers. This was partly due to the fact that the CCI has been relatively quiet on the cartel front for the last few months and partly because I have also been relatively busy with merger control work (which to many often comes across as quite drab compared to a juicy cartel case!).

However, breaking this prolonged silence, the CCI recently published a decision imposing fines on GSK and Sanofi, two major global pharma players as they were found to have rigged bids in a government tender for procurement of meningitis vaccines. Each year, in around May/June, the Government of India floats a tender for the purchase of QMMV (an anti-meningitis vaccine) for the purpose of vaccinating Indian pilgrims visiting Mecca on the ‘Hajj’ pilgrimage. There are only 3 major players supplying QMMV vaccines in India – GSK, Sanofi and Bio-Med (an Indian company). GSK is the largest supplier of this vaccine in the country.

The investigation of the CCI was based on a complaint by Bio-Med and related specifically to the tender floated in 2011 where Bio-Med had not been eligible to participate due to a minimum turnover requirement of the Government of India. In sum, the CCI found that the fact that GSK and Sanofi had each quoted to supply only roughly half of the tender quantity at roughly similar prices (which were significantly higher than the prices in the previous tender) constituted suspicious parallel behaviour for which the parties were unable to offer a rational explanation. The Government had raised the tender for roughly 180,000 doses of the vaccine and GSK had quoted to supply 100,000 doses at a price of INR 3000 per 10 dose vial and Sanofi had quoted to supply 90,000 doses at a price of INR 2899 per 10 dose vial. One common explanation offered by both parties was that the parties had not been able to quote for the entire tender quantity due to the extremely tight delivery schedule set by the Government. The CCI found that this tender being an annual one which was floated by the Government roughly around the same time each year, the parties would be easily able to estimate the delivery timelines in advance. Further, the CCI found that GSK had in fact, been able to supply much larger quantities of the vaccine in relatively short timeframes in previous tenders.

The CCI found that this suspicious parallel behaviour was corroborated by several factors such as the market conditions being conducive to collusion (limited suppliers who are repetitive bidders, homogenous product and fixed demand), no significant increase in cost of production to justify the sudden increase in the quoted price and representatives of both GSK and Sanofi having visited the Government department’s office on the same date.

The CCI imposed a penalty of 3% of the average turnover which resulted in a penalty of USD 9.4 million (approx.) on GSK and USD 0.4 million (approx.) on Sanofi.

I have kept this post purely factual without giving my views as my firm (including me for a very brief period) acted for Sanofi in this case. However, I will raise a couple of questions which come to mind and may be some food for thought:

1. Can the fact situation described above amount to parallel behaviour at all?
2. In the absence of any direct evidence, can the CCI simply prove parallel behaviour and shift the burden on the parties to provide a rational explanation, failing which a finding of collusion is to necessarily flow?
3. What is the strength of the corroborative evidence relied upon by the CCI in this case?

The full order of the CCI is available athttp://www.cci.gov.in/May2011/OrderOfCommission/27/262013.pdf